Anavex Life Sciences

AVXLNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$102.430 M

$1.11 -12.30%

Close of 6 Nov 2026

As of 6 Nov 2026, Anavex Life Sciences (AVXL) has a market capitalization of $102.4M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$46.4M

Loss-making

Shares outstanding

92,696,842

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#110Outlook TherapeuticsOTLK$107.3M
#111Voyager TherapeuticsVYGR$106.0M
#112Anavex Life SciencesAVXL$102.4M
#113Black Diamond TherapeuticsBDTX$95.7M
#114LENZ TherapeuticsLENZ$95.4M

What if Anavex Life Sciences were worth as much as…

Open the what-if tool →

Gold $28.2T

$304,615.27

Per share 275,670× higher

Bitcoin $1.53T

$16,482.20

Per share 14,916× higher

Apple $5.02T

$54,109.53

Per share 48,968× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Anavex Life Sciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.